A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2009-2013

ABSTRACT

Concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable, non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial. The purpose of this study was to evaluate the efficacy and toxicity of a concomitant treatment using Endostar (Recombinant Human Endostatin), Paclitaxel/Carboplatin and radiotherapy for LA-NSCLC, and also assess its impact on patient Quality of Life (QoL) and progression-free survival (PFS). Detailed Description Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment. More... »

URL

https://clinicaltrials.gov/show/NCT01158144

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable, non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial. The purpose of this study was to evaluate the efficacy and toxicity of a concomitant treatment using Endostar (Recombinant Human Endostatin), Paclitaxel/Carboplatin and radiotherapy for LA-NSCLC, and also assess its impact on patient Quality of Life (QoL) and progression-free survival (PFS).\n\nDetailed Description\nPatients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.", 
    "endDate": "2013-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01158144", 
    "keywords": [
      "Phase II", 
      "radiotherapy", 
      "patient", 
      "advanced non-small cell lung cancer", 
      "chemoradiotherapy", 
      "standard treatment", 
      "Non-Small-Cell Lung Carcinoma", 
      "chemotherapy regimen", 
      "efficacy", 
      "toxicity", 
      "endostatin", 
      "non small cell lung cancer", 
      "quality of life", 
      "QoL", 
      "Disease-Free Survival", 
      "cell", 
      "radiation therapy", 
      "fraction", 
      "Paclitaxel", 
      "carboplatin", 
      "D1", 
      "cycle", 
      "consolidation"
    ], 
    "name": "A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01158144"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00009.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417397.f", 
        "type": "Organization"
      }
    ], 
    "startDate": "2009-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s12885-016-2234-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009788378", 
          "https://doi.org/10.1186/s12885-016-2234-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-016-2234-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009788378", 
          "https://doi.org/10.1186/s12885-016-2234-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01158144"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01158144'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01158144'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01158144'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01158144'


 

This table displays all metadata directly associated to this object as RDF triples.

46 TRIPLES      16 PREDICATES      39 URIs      32 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01158144 schema:about anzsrc-for:3142
2 schema:description Concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable, non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial. The purpose of this study was to evaluate the efficacy and toxicity of a concomitant treatment using Endostar (Recombinant Human Endostatin), Paclitaxel/Carboplatin and radiotherapy for LA-NSCLC, and also assess its impact on patient Quality of Life (QoL) and progression-free survival (PFS). Detailed Description Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
3 schema:endDate 2013-12-01T00:00:00Z
4 schema:keywords D1
5 Disease-Free Survival
6 Non-Small-Cell Lung Carcinoma
7 Paclitaxel
8 Phase II
9 QoL
10 advanced non-small cell lung cancer
11 carboplatin
12 cell
13 chemoradiotherapy
14 chemotherapy regimen
15 consolidation
16 cycle
17 efficacy
18 endostatin
19 fraction
20 non small cell lung cancer
21 patient
22 quality of life
23 radiation therapy
24 radiotherapy
25 standard treatment
26 toxicity
27 schema:name A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer
28 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01158144
29 schema:sdDatePublished 2019-03-07T15:23
30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
31 schema:sdPublisher N2e22f97a63384873b233b33296e6f054
32 schema:sponsor https://www.grid.ac/institutes/grid.417397.f
33 schema:startDate 2009-10-01T00:00:00Z
34 schema:subjectOf sg:pub.10.1186/s12885-016-2234-0
35 schema:url https://clinicaltrials.gov/show/NCT01158144
36 sgo:license sg:explorer/license/
37 sgo:sdDataset clinical_trials
38 rdf:type schema:MedicalStudy
39 N2e22f97a63384873b233b33296e6f054 schema:name Springer Nature - SN SciGraph project
40 rdf:type schema:Organization
41 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
42 rdf:type schema:DefinedTerm
43 sg:pub.10.1186/s12885-016-2234-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009788378
44 https://doi.org/10.1186/s12885-016-2234-0
45 rdf:type schema:CreativeWork
46 https://www.grid.ac/institutes/grid.417397.f schema:Organization
 




Preview window. Press ESC to close (or click here)


...